Key Takeaways
- Sector: Healthcare Healthtech & Medtech.
- Geography: United States.
Analysis
Leading European private‑equity firms Astorg and Nordic Capital today announced a definitive agreement to sell their co‑controlling stakes in Clario, a global provider of digital endpoint solutions to the clinical‑trial industry, to Thermo Fisher Scientific (NYSE: TMO). The deal also sees exits by investors Novo Holdings and Cinven, marking what is described as the largest full‑healthcare private‑equity exit announced globally in 2025.
Headquartered in Philadelphia, Clario has become a critical partner to the life‑sciences industry. Over the past decade the company’s technology platform has supported more than 30,000 clinical trials and has been integral to approximately 70% of the approvals from the US Food and Drug Administration (FDA) and the European European Medicines Agency (EMA). Through a merger in 2021 of ERT and Bioclinica, followed by strategic acquisitions (including WCG’s eCOA business and NeuroRx in 2025), Clario scaled its platform across key therapeutic areas and enhanced its artificial‑intelligence‑enabled analytics capabilities.
Since the 2020 investment by Astorg and Nordic Capital (alongside Novo Holdings), Clario has doubled its revenue to approximately USD 1.2 billion, delivered strong margin expansion, invested heavily in technology and scaled to serve more than 600 life‑sciences customers worldwide. Astorg, Nordic Capital, Novo Holdings and Cinven supported management in strengthening the global operating model, expanding into broader therapeutic areas, and building an end‑to‑end digital endpoint and data‑intelligence business.
In commenting on the transaction, Clario CEO Chris Fikry said: “Over the past several years Clario has undergone a remarkable transformation – uniting industry leaders, advancing our scientific and technological capabilities, and strengthening our role as a trusted partner to the global life‑sciences community. Astorg and Nordic Capital have been instrumental in this journey… We are now excited to enter the next chapter with Thermo Fisher.”
For Astorg, Co‑Managing Partner and Head of Healthcare Judith Charpentier commented: “We are proud of our five‑year partnership with Clario, supporting the company as it grew into a cornerstone of the drug‑development industry. Together with management and co‑owners, we have strengthened Clario’s platform… We look forward to seeing Clario continue its growth story within Thermo Fisher.”
From Nordic Capital, Partner and Co‑Head of Healthcare & Head of U.S. Daniel Berglund added: “Since first investing in Clario in 2016, Nordic Capital has been proud to support the company’s journey… Clario now plays a vital role in enabling more patient‑centric and data‑driven clinical research. We have been honoured to contribute to this development and to see Clario so well‑positioned for its next chapter.”
The transaction remains subject to customary regulatory approvals and is expected to close by mid‑2026.
Context & Market Implications
This deal reflects several broader trends in the global healthcare private‑equity market. According to the 2025 Global Healthcare Private Equity Report from Bain & Company, healthcare‑PE dealmaking continues to show momentum with megadeals dominating the landscape, even as macro‑economic headwinds (such as higher interest rates and exit timing challenges) remain. Exits have remained constrained, with value creation increasingly dependent on operational transformation rather than relying solely on multiple expansion.
In this case, the sellers achieved value creation through revenue growth, margin improvement and strategic technology scaling—aligning with the industry shift described by Bain: “deal‑makers’ growing interest in clinical‑trial IT, digital endpoints, and biopharma services”.
Importantly, for the buyer Thermo Fisher, the acquisition of Clario marks a strong move deeper into digital clinical trial services and endpoints, a sector viewed as more resilient and higher margin than early‑stage drug research. This supports Thermo Fisher’s pivot towards higher‑growth life‑sciences services and data‑driven platforms.